Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to compare the difference in the proportion of patients with tolerable pain scores, VAS pain scores, quality of recovery and opioid use in milligram equivalents (at 24, 48, 72, 96 and 120 hours postoperatively) in patients undergoing shoulder arthroplasty who receive interscalene blocks with or without Liposomal Bupivacaine. This is a prospective randomized, double-blinded, controlled trial that will enroll 130 subjects undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty. Participants who meet all eligibility criteria will be randomized in a 1:1 ratio to receive either 36 mL of 0.5% bupivacaine (PB group) or 10 mL of liposomal bupivacaine and 20 mL of 0.25 % bupivacaine and 6 mL of saline (LB group).


Clinical Trial Description

Patients undergoing shoulder surgery can suffer from significant postoperative pain which can lead to an increase in recovery time, opioid use and potential dependency, and a decrease in quality of recovery. The interscalene brachial plexus block is a common effective regional anesthesia technique used for a variety of procedures involving the shoulder. The number of total shoulder arthroplasty surgeries being performed annually in the United States are increasing every year. Liposomal bupivacaine was FDA approved for use in patients undergoing interscalene block in 2018 to reduce postoperative pain from shoulder surgery. The information from the manufacturer indicates that the liposomal encapsulation may release the drug for up to approximately 72 hours after it has been administered, providing a prolonged analgesic effect. Evidence to the prolonged analgesic effect of liposomal bupivacaine has varied in the current literature. A recent meta-analysis suggested that liposomal bupivacaine may provide a statistically significant, but clinically insignificant decrease in opioid consumption and pain scores over time. The authors noted a possible limitation of their study is that the meta-analysis included a variety of surgical procedures and block techniques, and was not specific to shoulder surgery or interscalene block. The authors noted that this variability in anesthetic regimens between study groups could have affected the observed outcomes. Recently, the investigators performed a retrospective quality improvement study to investigate the potential benefit of liposomal bupivacaine used for interscalene blocks among 491 patients undergoing shoulder arthroplasty between 2018 and 2021. The investigators compared the difference in the proportion of patients with clinically tolerable pain scores (defined as VAS ≤ 4) in those patients receiving liposomal bupivacaine vs. those receiving another local anesthetic (plain bupivacaine, mepivacaine or ropivacaine) vs. those receiving no block. The results of this study suggested there was significant difference in the proportion of patients with clinically tolerable pain scores when receiving liposomal bupivacaine during all observations and at 3 days postoperatively versus those patient that did not. The patients who received liposomal bupivacaine also had a significant reduction in morphine milligram equivalents (MMEs). Based on the investigators retrospective results, the investigators performed a power analysis which allowed for the development of this prospective randomized double blinded trial comparing liposomal bupivacaine plus plain bupivacaine vs. plain bupivacaine only in near equipotent doses. The investigators believe that this is a very important and unique trial to perform as it could change the way pain management is delivered in this patient population. Longer acting local anesthetic used for interscalene blocks may increase the number of patients who have tolerable pain and require less or no opioids. This could reduce or inevitably eliminate the unwanted effects of opioids (nausea, vomiting, constipation, urinary retention, opioid induced respiratory depression, dependency and addiction) and result in an improvement in the quality of recovery of patients undergoing total shoulder arthroplasties. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05900427
Study type Interventional
Source NorthShore University HealthSystem
Contact Johnny K Lee, MD
Phone 847-570-2760
Email JLee8@northshore.org
Status Recruiting
Phase Phase 4
Start date September 8, 2023
Completion date October 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT01430468 - Patient Specific Instruments Versus Standard Surgical Instruments N/A
Completed NCT03730597 - Glenosphere Size and Scapular Notch in RSA, Prospective Randomized Study N/A
Completed NCT01782872 - Analgesia After Total Shoulder Arthroplasty Phase 4
Completed NCT06109415 - A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Phase 4
Active, not recruiting NCT03623269 - Posterior Approach to Total Shoulder Arthroplasty
Terminated NCT03219983 - Pain Management After Total Shoulder Arthroplasty Phase 4
Completed NCT01726972 - A Retrospective Review of FloSeal Use in Total Shoulder Arthroplasty
Enrolling by invitation NCT06133933 - Total Shoulder Arthroplasty Preoperative Pain Threshold and Association With Postoperative Opioid Consumption
Suspended NCT04416932 - Ultrasound After Total Shoulder Arthroplasty
Completed NCT04855019 - Post Surgical Pain in Arthroscopic Shoulder N/A
Recruiting NCT06143306 - Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement Phase 4
Completed NCT03887650 - LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs Phase 4
Recruiting NCT05068960 - Postoperative Pain Control in Total Shoulder Arthroplasty Phase 4
Active, not recruiting NCT02143245 - Diagnostic Accuracy of Synovial Biopsy for Implant-Related Shoulder Infections N/A
Completed NCT01550952 - Interscalene Dynamometer Pilot Study N/A
Completed NCT03969875 - Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone
Completed NCT04364867 - Exparel for Total Shoulder Arthroplasty Phase 4